AI Investors Face a New Due Diligence Test on Safety

A blunt question to venture capital: are investors examining the safety risks of artificial intelligence companies before financing their growth?

The question reaches far beyond a founder’s ethics slide. An AI system that produces harmful instructions, leaks customer information, relies on disputed data or fails under routine attempts to bypass its safeguards can create regulatory costs, contract disputes and customer departures. Those outcomes eventually arrive in the financial model, usually after the pitch deck has converted them into a reassuring bullet called responsible AI.

Safety therefore belongs in commercial due diligence alongside revenue quality, customer concentration and gross margin. The challenge is defining what an investor should examine, how deeply a generalist fund can examine it and whether the investor has any incentive to slow a competitive deal.

International Business Times frames the pressure from another direction: AI chief executives themselves have warned that the technology race is moving too fast, with investors potentially exposed to the consequences. The public record supplied for this story does not establish how widely venture firms have adopted formal safety reviews, so broad claims about industry practice would outrun the available evidence. The sharper issue is what credible diligence would look like if funds treated safety as a business risk rather than decorative compliance.

What Investors Could Actually Check

AI safety covers several layers that often get flattened into one phrase. A company developing a foundation model faces different hazards from a startup wrapping an external model in software for hospitals, recruiters or customer-service teams. The first may need to explain model evaluations, training data, access controls and misuse testing. The second still has to understand those dependencies, but its largest exposure may sit in workflow design, human review and customer promises.

A useful review starts with the product’s intended use and predictable misuse. Investors can ask what happens when a model hallucinates, follows a hostile prompt, reveals protected information or gives a confident answer outside its tested domain. They can request evidence from evaluations and adversarial testing, rather than accepting a polished demo conducted on friendly prompts.

Data deserves its own workstream. A startup should be able to explain where training and retrieval data come from, what rights govern their use, how customers can remove information and whether sensitive data can enter model outputs. Answers such as industry standard or proprietary process offer little protection when a customer, regulator or rights holder asks for the underlying record.

The operational questions are less glamorous and often more revealing:

• Who receives an incident report, and how quickly?
• Can the company disable a feature or model deployment without taking down the whole product?
• What logs exist for reconstructing a failure?
• When must a human approve an output?
• Have safeguards been tested against bypass attempts?
• Do customer contracts promise more accuracy or security than the system can deliver?
• Who absorbs the cost of refunds, legal claims, remediation or regulatory action?

None of this gives investors certainty. Tests can miss novel failures, models change and startups depend on suppliers whose own systems remain opaque. Diligence can still identify a company that has never assigned responsibility for incidents, cannot trace key data or has written contractual checks its product cannot cash.

The Speed Argument Has Substance

Founders and investors have credible reasons to resist an ever-expanding diligence ritual. Early-stage companies have limited cash and small teams. A seed startup using a third-party model cannot reproduce the testing budget of a frontier laboratory. Requiring every founder to commission extensive audits could favor incumbents and turn compliance spending into a moat for companies already rich enough to build one.

Investors also face an expertise problem. A partner who has spent a decade funding consumer marketplaces does not become an AI evaluator after adding a safety section to the investment memo. Outside consultants can help, although their methods and independence require scrutiny too. A confident report based on a narrow test may create more comfort than knowledge.

Speed also carries economic value. Products improve through deployment, customer feedback and iteration. Excessively rigid review can freeze an early design or delay tools whose benefits exceed their risks. The appropriate burden should track the use case. A writing assistant and an automated system influencing access to employment, credit or medical care do not present the same severity of harm.

That distinction protects safety diligence from becoming a generic brake pedal. Investors can scale their review according to the model’s autonomy, the sensitivity of its data, the reversibility of errors and the population exposed. The goal is a risk map tied to an actual product, not a 70-page policy copied from a company selling something else.

Venture Incentives Complicate the Review

VC portfolios rely on a small number of large winners to return a fund. That structure rewards access to high-growth deals and punishes hesitation when rival firms are ready to sign. A safety review that delays a term sheet can look prudent in an investment committee and fatal in a founder’s allocation process.

The asymmetry runs deeper. A fund captures its ownership share when an AI company grows rapidly. Workers, customers and public agencies may carry costs when deployment fails. Investors still face losses through reduced company value, reputational damage and legal exposure, depending on the facts and jurisdiction, but those costs do not automatically equal the harm imposed outside the cap table.

The wider market already struggles to price enormous AI spending against uncertain returns, as diverging reactions to AI investments at Meta and Microsoft have shown. Startup investors face an even murkier calculation because private-company disclosures are thinner and product risks can change between financing rounds.

Compensation inside venture firms matters as well. A partner may receive internal credit for winning a coveted deal years before safety failures surface. Management fees arrive during the holding period. Carried interest appears if the company produces gains. The system has fewer automatic rewards for the investment that a partner declined after finding weak controls.

Funds can counter that pressure through process. They can require risk reviews before final approval, use independent specialists, reserve board reporting rights for serious incidents and make follow-on financing contingent on agreed controls. These measures carry trade-offs: board oversight can drift into operational micromanagement, and contractual conditions can give investors leverage over founders who have little room to refuse.

Safety Risk Eventually Reaches the Cap Table

Liquidation preferences show how a company’s downside gets divided. Consider a hypothetical startup raising $20 million at an $80 million pre-money valuation. The new investor owns 20% and receives a standard 1x non-participating liquidation preference. If the company later sells for $50 million after a damaging product failure, the investor can take the $20 million preference instead of converting into common shares worth $10 million. Founders, employees and earlier common holders divide the remaining $30 million. At a $200 million sale, the investor would convert and take $40 million.

That math does not immunize the investor. The fund can still lose money after accounting for time and opportunity cost, while a severe failure may erase the company’s value altogether. It does show why employees need to understand the preference stack when management says everyone shares the downside. They often do not share it in the same order.

Later rounds can sharpen the imbalance through senior preferences, participation rights or down-round protections. A startup confronting a safety crisis may need emergency capital when its negotiating power is weakest. New financing can keep the company alive while diluting common shareholders and placing another preference above them. Safety failures that sounded abstract during the seed round can become cap-table arithmetic during the rescue round.

Disclosure Will Separate Process from Theater

Founders also have reason to scrutinize investors. A fund demanding extensive safety representations may be preparing useful governance, or shifting future blame toward management. Founders should ask who evaluates the risk, what standard applies, how incidents will be handled and whether the investor will fund the controls it expects.

Employees have fewer bargaining tools, yet they may be asked to ship systems whose limits they understand better than the board. Clear escalation channels, protection for internal reporting and documented launch criteria can make safety operational. A policy that collapses whenever a sales target is threatened belongs to marketing.

Customers can exert the fastest pressure of all. Enterprise buyers may demand audit rights, security documentation, performance commitments and disclosure of model suppliers. Those requirements can convert safety spending into a sales asset. They can also lengthen sales cycles and strain margins, particularly when each customer requests a different review.

No checklist will resolve the central incentive conflict. Investors compete to own companies before their risks are fully visible, while AI startups compete to deploy systems before their behavior is fully understood. The next serious test will come when a coveted deal has weak safeguards, a short allocation window and several funds waiting outside the room. The diligence memo will matter only if someone is willing to act on it.